Trials / Unknown
UnknownNCT03536780
Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
Phase II Trial of Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Gachon University Gil Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2 trial of avelumab plus gemcitabine in advanced leiomyosarcoma as a second line treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab and Gemcitabine | * Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks * Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2021-12-31
- Completion
- 2022-12-31
- First posted
- 2018-05-25
- Last updated
- 2021-02-04
Locations
6 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03536780. Inclusion in this directory is not an endorsement.